Evidence map›Paper›PMID 42712445›Full record

SynthesisFrontiers in pharmacology2026

Association of germline

Marina-Daniela Dimulescu, Cristian Virgil Lungulescu, Anca-Lelia Riza, Ioana Streata, Radu Antoniu Patrascu, Anca-Maria Capraru, Mihaela-Simona Naidin, Bogdan Silviu Ungureanu, Ioana Andreea Gheonea, Adina Turcu-Stiolica

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marina-Daniela DimulescuDoctoral School, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Cristian Virgil LungulescuOncology Department, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Anca-Lelia RizaDepartment of Genetics, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Ioana StreataDepartment of Genetics, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Radu Antoniu PatrascuDoctoral School, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Anca-Maria CapraruDoctoral School, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Mihaela-Simona NaidinDepartment of Pharmaceutical Management and Marketing, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Bogdan Silviu UngureanuDepartment of Gastroenterology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Ioana Andreea GheoneaDepartment of Radiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Adina Turcu-StiolicaDepartment of Pharmacoeconomics, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: CDK4/6 inhibitors are standard-of-care for HR+/HER2- advanced breast cancer, but grade 3/4 neutropenia occurs in up to 60% of patients. Germline polymorphisms in Methods: PubMed, Scopus, and Web of Science were systematically searched. Studies reporting genotype-stratified grade 3/4 neutropenia in CDK4/6 inhibitor-treated patients were eligible. Four SNPs were analyzed: Results: Four studies (1,138 patients) were included. No SNP showed a significant overall association. However, significant ancestry-dependent heterogeneity was detected for two Conclusion: These preliminary findings suggest that Systematic Review Registration: identifier CRD420261379298.

Indexed as

ABCB1cancerCDK4/6 inhibitorERCC1neutropeniapalbociclibpharmacogenomics

Identifiers

PMID42712445
PMCPMC13550004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.